Hepatoblastoma: recent developments in research and treatment

Area of Science:

• Pediatric Oncology
• Hepatobiliary Malignancies
• Molecular Pathology

Background:

• Hepatoblastoma is the predominant liver tumor in early childhood.
• Increasing incidence rates are observed in North America and Europe.
• Recent histological discoveries challenge existing classifications, prompting a revised international system.

Purpose of the Study:

• To address the evolving understanding of hepatoblastoma classification.
• To identify prognostically significant gene signatures and therapeutic molecular targets.
• To harmonize risk stratification and treatment strategies among international study groups.

Main Methods:

• Pooling patient data from multicentric US, European, and Japanese study groups.
• Analysis of prognostic criteria for defining common risk groups.
• Review of recent research on gene signatures and molecular targets.

Main Results:

• Established treatment recommendations include cisplatin-based chemotherapy for neoadjuvant and adjuvant settings.
• Significant differences exist in current risk stratification and treatment strategies across major study groups.
• Cure rates are high for standard-risk (90%) and high-risk (65%) hepatoblastomas.

Conclusions:

• The dismal prognosis for multifocal, disseminated, and metastatic hepatoblastoma necessitates further investigation.
• New cytotoxic drugs and targeted molecular therapies are crucial for improving outcomes in advanced disease.
• Collaborative data analysis aims to establish unified risk groups and treatment protocols for hepatoblastoma.